Cagrilintide
Cagrilintide (NN9838)
Just when we thought GLP-1 agonists had peaked, researchers started looking at amylin. Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk specifically to run alongside semaglutide. The combination, dubbed CagriSema in clinical trials, produces weight loss numbers that straight-up rival bariatric surgery. It attacks appetite from a completely different neurological angle than tirzepatide or semaglutide, making it the ultimate plateau-breaker for subjects who have stalled on standard therapies.
Buy Cagrilintide at Peptide PalacePurity
99%+
Molecular Weight
4429.1 g/mol
Administration
Subcutaneous injection
Storage
Store lyophilized powder in the freezer at -20°C
Mechanism of Action
Instead of hitting the GLP-1 or GIP receptors, cagrilintide targets amylin and calcitonin receptors in the hindbrain. It signals absolute fullness and heavily delays gastric emptying. Because it operates on an entirely separate biological pathway from the incretin mimetics, stacking it with a GLP-1 creates a synergistic metabolic blockade against hunger. You are essentially telling the brain's satiety centers to shut down appetite from two different directions simultaneously.
Sequence:
KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY (with C16 diacid modification at Lys, disulfide bridge between Cys2-Cys7, and C-terminal amide) Research Areas
- Amylin receptor agonism
- Synergistic obesity treatments (GLP-1 combinations)
- Type 2 diabetes glycemic control
- Cardiovascular risk reduction in obese models
- Gastric emptying modulation
Potential Benefits
- Extreme appetite suppression
- Overcomes GLP-1 resistance and weight-loss plateaus
- Significant reductions in overall body weight
- Improved insulin sensitivity
- Prolonged gastric emptying for extended satiety
Research Dosing Guidelines
For research purposes only. Not for human consumption.
Typical Dose
0.25 mg - 2.4 mg
Frequency
Once weekly
Duration
16-24 weeks
Administration
Subcutaneous injection
Most researchers start at an absolute baseline of 0.25mg weekly, especially if stacking with a GLP-1. The nausea is intense if you titrate too fast. The sweet spot in clinical trials tops out at 2.4mg of cagrilintide alongside 2.4mg of semaglutide, but very few subjects need to run it that high to see massive drops.
Reconstitution Calculator
U-100 Insulin Syringe
For research and educational purposes only. Always follow proper reconstitution and sterile handling protocols.
The CagriSema Combination: Why Dual Pathways Matter
Cagrilintide's greatest potential lies in combination with semaglutide — a regimen dubbed "CagriSema" — which targets two completely independent appetite-regulating pathways simultaneously.
Mono vs Combination Therapy
| Factor | Semaglutide Alone | Cagrilintide Alone | CagriSema (Combined) |
|---|---|---|---|
| Pathway | GLP-1 receptor | Amylin/calcitonin receptor | Both simultaneously |
| Average weight loss | ~15% | ~10-11% | ~15-17% (early data) |
| Appetite mechanism | Central satiety signaling | Hindbrain fullness + gastric delay | Dual suppression |
| Plateau resistance | Plateaus common at 40-60 weeks | Limited data | Designed to overcome GLP-1 plateaus |
The biological rationale is straightforward: when one satiety pathway adapts and weight loss stalls, the second pathway maintains continued suppression. Clinical trials are evaluating whether this dual approach can achieve surgical-level weight loss without surgery.
Potential Side Effects
- Severe nausea (especially during dose escalation)
- Vomiting and GI distress
- Fatigue and lethargy
- Gastric stasis (food sitting in the stomach too long)
Storage Requirements
Store lyophilized powder in the freezer at -20°C. Reconstitute with bacteriostatic water and keep in the fridge at 2-8°C. Use within 30 days.
Research References
- [1]Efficacy and safety of cagrilintide for weight management: a randomised, double-blind, placebo-controlled, phase 2 dose-finding study (2021)Strong Evidence Population: Adults with BMI ≥30 or ≥27 with comorbidities (n=706)
Cagrilintide induced significant, dose-dependent weight loss compared to placebo, establishing its efficacy as a standalone weight management agent.
Limitations: 26-week duration; long-term safety and weight maintenance not assessed
- [2]Efficacy and safety of co-administered cagrilintide and semaglutide for weight management (2021)Strong Evidence Population: Adults with obesity without diabetes (n=92)
The combination of cagrilintide and semaglutide produced significantly greater weight loss than either peptide administered alone, proving their synergistic mechanism.
Limitations: Phase I trial; small sample; short 20-week treatment period
- [3]Once-weekly cagrilintide, a novel long-acting amylin analogue, for weight management (2022)Preclinical Population: Review of Phase I/II cagrilintide clinical data
Amylin analogues like cagrilintide represent a distinct and highly effective alternative pathway for combating obesity independent of GLP-1 receptor agonism.
Limitations: Narrative review; no Phase III trial data available at time of publication
Frequently Asked Questions
What is Cagrilintide?
Cagrilintide is a long-acting amylin analogue designed to mimic the satiety hormone amylin. Researchers primarily study it as an add-on therapy to GLP-1 agonists to dramatically increase weight loss and appetite suppression.
What are the potential research benefits of Cagrilintide?
The primary benefit is aggressive weight loss and appetite control. Because it targets amylin and calcitonin receptors rather than GLP-1, it helps subjects break through weight loss plateaus when other incretin therapies stop working.
How is Cagrilintide typically dosed in research?
Research subjects typically receive 0.25 mg weekly via subcutaneous injection to start, slowly titrating up to a maximum of 2.4 mg weekly over several months. It is frequently administered alongside an equal dose of a GLP-1 agonist.
What are the side effects of Cagrilintide?
Nausea and delayed gastric emptying are the most common and limiting adverse reactions. If the dose is increased too quickly, severe vomiting and gastrointestinal distress are highly likely.
How should Cagrilintide be stored?
Keep lyophilized powder in the freezer at -20°C. Once reconstituted with bacteriostatic water, store vials in the refrigerator at 2-8°C and use within 30 days.
Ready to Purchase Cagrilintide?
Get the highest quality Cagrilintide from our recommended vendor with 99%+ purity guaranteed.
Buy at Peptide PalaceRelated Topics
Peptide Hormones and Their Functions
Peptide hormones are hydrophilic signaling molecules that bind cell surface receptors, triggering intracellular cascades via second messengers like cAMP and calcium.
Peptide-Drug Conjugates (PDCs)
PDCs combine targeting peptides with cytotoxic payloads to deliver drugs specifically to diseased cells, occupying a niche between small molecules and antibody-drug conjugates.
Safety & Reference
Related Peptides
Semaglutide
Semaglutide Acetate
Semaglutide is a GLP-1 receptor agonist that mimics the effects of the naturally occurring hormone GLP-1. It has gained significant attention for its powerful effects on appetite regulation and blood sugar control, leading to substantial weight loss in research subjects.
Learn MoreTirzepatide
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist, representing a new class of medications for metabolic conditions. It has shown remarkable efficacy in weight loss and glycemic control studies, often surpassing the results of single-receptor agonists.
Learn MoreMazdutide
Mazdutide (IBI362 / LY3305677)
Developed originally by Eli Lilly and advanced by Innovent Biologics, Mazdutide (IBI362) functions as a dual GLP-1 and glucagon receptor agonist. Think of it as a synthetic, long-acting version of oxyntomodulin, a naturally occurring hormone that kills appetite while actively burning stored fat. The clinical data out of China right now is staggering, especially regarding its ability to aggressively clear out liver fat while matching or beating the weight loss seen with standard single-agonist drugs.
Learn MoreRetatrutide
Retatrutide (LY3437943)
Retatrutide is the heavyweight champ of the incretin world right now. Eli Lilly engineered this 39-amino-acid peptide to hit three different receptors at once: GLP-1, GIP, and Glucagon. While semaglutide targets one pathway and tirzepatide hits two, retatrutide's 'triple G' approach pushed clinical trial weight loss past the 24% mark in under a year. We haven't seen anything this potent before outside of bariatric surgery.
Learn More